Age, mean years ± SD |
51.6 ± 15.6 |
15.6 ± 14.6 |
52.0 ± 16.7 |
0.894 |
Male |
42 (46.7) |
16 (35.6) |
26 (57.8) |
0.035 |
Weight, mean kg ± SD |
57.76 ± 1.50 |
58.94 ± 1.94 |
60.57 ± 2.30 |
0.590 |
Cause of febrile neutropenia |
|
|
|
|
Cytotoxic chemotherapy |
67 (74.4) |
34 (75.6) |
33 (73.3) |
1.000 |
During period of initial hematologic abnormalities diagnosis |
20 (22.2) |
10 (22.2) |
10 (22.2) |
1.000 |
Other causesa
|
3 (3.33) |
1 (2.22) |
2 (4.44) |
1.000 |
Active hematologic cancer |
72 (80) |
34 (75.6) |
38 (84.4) |
0.496 |
Active solid cancer |
8 (8.9) |
4 (8.9) |
4 (8.9) |
0.496 |
MASCC score, median (IQR) |
20 (17-21) |
19 (13-21) |
21 (19-21) |
0.129 |
High risk of febrile neutropenia (MASCC<21) |
45 (50) |
25
(55.6) |
20 (44.4) |
0.292 |
Absolute neutrophil count, median cells/mm3 (IQR) |
153.9 (19– 520) |
184 (40-645) |
77 (13-368) |
0.198 |
Had history of febrile neutropenia |
46 (51.1) |
20 (44.4) |
26 (57.8) |
0.206 |
Recent exposed to antibiotic within past 3 months |
50 (55.6) |
25
(55.6) |
25 (55.6) |
1.000 |
Neutropenia duration, median days (IQR) |
7 (4-14) |
8 (4-14) |
6 (4-10) |
0.435 |
Infectious diseases specialist consultation |
50 (55.6) |
27 (60) |
23
(51.1) |
0.396 |
Time to administer antibiotic, median hours (IQR) |
1 (0-4) |
1.5 (0-4) |
1 (0-4) |
0.497 |
Microbiological data |
|
|
|
|
Causative organism identified |
49 (54.4) |
26 (57.8) |
23 (51.1) |
0.525 |
Gram positive bacteria |
12 (13.3) |
7 (15.6) |
5 (11.1) |
0.774 |
Gram negative bacteria |
39 (43.3) |
20 (44.4) |
19 (42.2) |
0.761 |
ESBL-producing organisms |
12 (13.3) |
3 (6.7) |
9 (20) |
0.118 |
Carbapenem resistance organisms |
5 (5.6) |
4 (8.9) |
1 (2.2) |
0.361 |